PARAMETHADIONE

Details

Stereochemistry	RACEMIC
Molecular Formula	C7H11NO3
Molecular Weight	157.1671
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1(C)OC(=O)N(C)C1=O

InChI

InChIKey=VQASKUSHBVDKGU-UHFFFAOYSA-N

InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C7H11NO3
Molecular Weight	157.1671
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19298435
Curator's Comment: Other drugs of oxazolidinedione class act by blocking T-type calcium channel (see , but there is no information about interaction between paramethadione

Paramethadione is an anticonvulsant in the oxazolidinedione class developed by the Abbott Laboratories, approved by the Food and Drug Administration in 1949 for the treatment of absence seizures, also called partial seizures. Paramethadione acts to reduce T-type calcium currents in thalamic neurons which has been proposed to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram (EEG) during absence seizures.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated T-type calcium channel 19 Target ID: CHEMBL2362995 Sources: https://www.drugs.com/mmx/paramethadioneanticonvulsants-dione.html	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
Absence seizures 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14394344	Primary		Approved 8583	PARADIONE Approved Use Paramethadione, an oxazolidinc derivative (300 mg p.o. t.i.d.), is indicated as an alternate drug in the treatment of refractory absence seizures. Paramethadione raises the threshold for cortical seizures but does not modify the seizure pattern. It decreases projection of focal activity and reduces both repetitive spinal cord transmission and spike-and-wave patterns of absence (petit mal) seizures. Launch Date 1949

C_max

Value	Dose	Co-administered	Analyte	Population
6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1185541	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PARAMETHADIONE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1185541	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		5-ETHYL-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1185541	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PARAMETHADIONE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1185541	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		5-ETHYL-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
300 mg single, oral Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1185541/	healthy, 30 - 41 years Health Status: healthy Age Group: 30 - 41 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/1185541/	Sources: https://pubmed.ncbi.nlm.nih.gov/1185541/
300 mg 3 times / day steady, oral Dose: 300 mg, 3 times / day Route: oral Route: steady Dose: 300 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4193708/	healthy, adult Health Status: healthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4193708/	Other AEs: Teratogenicity... Other AEs: Teratogenicity Sources: https://pubmed.ncbi.nlm.nih.gov/4193708/

AEs

AE	Significance	Dose	Population
Teratogenicity		300 mg 3 times / day steady, oral Dose: 300 mg, 3 times / day Route: oral Route: steady Dose: 300 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4193708/	healthy, adult Health Status: healthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4193708/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C8 810 CYP2E1 729

Drug as victim

Target	Modality	Activity
CYP2C9 1193	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00617	major
CYP2C8 810	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00617	yes
CYP2E1 729	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00617	yes
CYP3A4 1946	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00617	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY508010	https://www.001chemical.com/chem/115-67-3
AHH Chemical co.,ltd	MR-1013790	http://www.ahhchemical.com/product/MR-1013790.html
Ambinter	Amb10843640	http://www.ambinter.com/reference/10843640
BLD Pharm	BD146751	http://www.bldpharm.com/products/115-67-3.html
ChemMol	49400434	http://www.chemmol.com/chemmol/49400434.html
Clearsynth	CS-T-38691	https://www.clearsynth.com/en/CST38691.html
eNovation Chemicals	D675465	https://www.enovationchem.com/ProductDetails.asp?ProductID=D675465
iChemical	EBD26815	http://www.ichemical.com/chemicals/cas-115-67-3
Molcore	MC508010	https://www.molcore.com/product/115-67-3
OChem	30682	http://www.ocheminc.com/index.php?act=psearch&pid=115P673

PubMed

Title	Date	PubMed
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.	2010	22291486
The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome.	1977-12	412416
Paramethadione and metabolite serum levels in humans after a single oral paramethadione dose.	1975-10	1185541
Possible teratogenicity of trimethadione and paramethadione.	1970-08-01	4193708
Nephrotic syndrome caused by probenecid.	1967-01-02	6071127

Patents

Sample Use Guides

In Vivo Use Guide

For treatment of epilepsy in children, Paramethadione should be administered orally, 300-600 mg 2-3 times a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:47:44 GMT 2025` Edited by `admin` on `Mon Mar 31 17:47:44 GMT 2025`
Record UNII	Z615FRW64N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PARAMETHADIONE

Official Name

English

PARADIONE

Preferred Name

English

3,5-DIMETHYL-5-ETHYLOXAZOLIDINE-2,4-DIONE

Systematic Name

English

PARAMETHADIONE [HSDB]

Common Name

English

5-ETHYL-3,5-DIMETHYLOXAZOLIDINE-2,4-DIONE

Systematic Name

English

PARAMETHADIONE [ORANGE BOOK]

Common Name

English

ISOETHADIONE

Common Name

English

PARAMETHADIONE [MI]

Common Name

English

PARAMETHADIONE [VANDF]

Common Name

English

5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione

Systematic Name

English

Paramethadione [WHO-DD]

Common Name

English

paramethadione [INN]

Common Name

English

2,4-OXAZOLIDINEDIONE, 5-ETHYL-3,5-DIMETHYL-

Systematic Name

English

PARAMETHADIONE [MART.]

Common Name

English

NSC-760129

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C264